GSK completed the acquisition of IDRx for $1.15bn.

GSK, a British multinational pharmaceutical and biotechnology company, completed the acquisition of IDRx, a Boston-based, clinical-stage biopharmaceutical company, for $1.15bn. "We are looking forward to working with GSK to advance IDRX-42 for patients with GIST given there have been no major advances to the standard of care for almost 20 years. Combining our experience to date with GSK's expertise in GI cancers, global clinical development capability, and strong commercial presence in oncology will help to accelerate the development of this novel medicine for patients," Tim Clackson, IDRx CEO.